Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Thumb Arthritis Market Trends

ID: MRFR/MED/3800-HCR
90 Pages
Rahul Gotadki
March 2026

Thumb Arthritis Market Research Report Information By Diagnosis (Physical Examinations, Imaging, FNA), By Type (Osteoarthritis, Rheumatoid), By Treatment (Thumb Exercise, Medication, Surgery), By End Users (Hospitals & Clinics, Retail Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Thumb Arthritis Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Thumb Arthritis Market

The Thumb Arthritis market is experiencing a boom due to the increasing prevalence of Thumb Arthritis, in particular most of the growing older population. As human beings age, the wear and tear and tear at the joints, mixed with genetic elements, contribute to the improvement of Thumb Arthritis, driving the demand for effective remedies. There is a developing emphasis on recognition and early analysis of Thumb Arthritis. Healthcare experts and patients have become extra knowledgeable about the symptoms and chance elements, leading to early detection and proactive management. The market tendencies in Thumb Arthritis mirror a shift in the direction of non-surgical interventions. Advances in conservative treatments, inclusive of medications, physical remedies, and orthotics, are gaining prominence. Patients are an increasing number of in search of non-invasive options to manipulate Thumb Arthritis, influencing market dynamics. The exploration of biological treatment plans and injectable remedies for Thumb Arthritis is evolving. Researchers and pharmaceutical businesses are investigating the effectiveness of biologics, inclusive of platelet-rich plasma (PRP) and hyaluronic acid injections, in assuaging signs and slowing down the development of Thumb Arthritis. Market players are adopting an affected person-centric technique in the development of products for Thumb Arthritis. There is a focal point on understanding the affected person's desires, options, and way of life considerations to design answers that decorate typical excellent lifestyles. This method consists of the customization of orthopedic devices and treatment plans. The integration of telemedicine into the management of Thumb Arthritis is becoming more frequent. Telemedicine allows sufferers to talk with healthcare experts remotely, facilitating observe-up appointments and presenting admission to professionals without the need for frequent in-individual visits; it is mainly useful for people with mobility barriers. Collaborative efforts among orthopedic surgeons and rheumatologists are shaping the Thumb Arthritis market. This interdisciplinary approach ensures a comprehensive understanding of the ailment. It enables the development of included remedy techniques that cope with each of the structural and inflammatory aspects of Thumb Arthritis. Changes in healthcare rules and insurance coverage influence the Thumb Arthritis market. Access to innovative remedies, compensation regulations for surgical methods and conservative treatment options, and the affordability of specialized orthopedic devices are factors that affect the market landscape.

Author
Author Profile
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Thumb Arthritis Market?

<p>The Thumb Arthritis Market was valued at 466.56 USD Million in 2024.</p>

What is the projected market size for the Thumb Arthritis Market by 2035?

<p>The market is expected to reach 1144.78 USD Million by 2035.</p>

What is the expected CAGR for the Thumb Arthritis Market during the forecast period?

<p>The expected CAGR for the Thumb Arthritis Market from 2025 to 2035 is 8.5%.</p>

Which types of arthritis are included in the Thumb Arthritis Market segmentation?

<p>The market segments include Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, and Gout.</p>

What were the market values for Osteoarthritis and Rheumatoid Arthritis in 2024?

<p>In 2024, Osteoarthritis was valued at 186.56 USD Million, while Rheumatoid Arthritis was valued at 120.0 USD Million.</p>

How does the market for assistive devices compare to other treatment types?

<p>Assistive Devices were valued at 93.31 USD Million in 2024, similar to Physical Therapy and Surgical Intervention.</p>

What age groups are represented in the Thumb Arthritis Market?

The market segments by age group include Children, Adults, and the Elderly.

What were the market values for the elderly and adults in 2024?

In 2024, the market value for the Elderly was 166.56 USD Million, while Adults accounted for 250.0 USD Million.

Which companies are considered key players in the Thumb Arthritis Market?

Key players include Johnson &amp; Johnson, Medtronic, Stryker Corporation, and Zimmer Biomet.

What severity levels are recognized in the Thumb Arthritis Market?

The market recognizes Mild, Moderate, and Severe severity levels, with Moderate valued at 186.88 USD Million in 2024.

Market Summary

As per MRFR analysis, the Thumb Arthritis Market Size was estimated at 466.56 USD Million in 2024. The Thumb Arthritis industry is projected to grow from 506.23 USD Million in 2025 to 1144.78 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 8.5% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Thumb Arthritis Market is experiencing a dynamic shift towards innovative treatment solutions and preventive care strategies.

  • Technological integration in treatment is becoming increasingly prevalent, enhancing patient outcomes and engagement.
  • There is a growing emphasis on preventive care, reflecting a proactive approach to managing thumb arthritis.
  • Personalized treatment approaches are gaining traction, catering to the unique needs of patients across diverse demographics.
  • The aging population and advancements in treatment technologies are driving market growth, particularly in North America and the Asia-Pacific region.

Market Size & Forecast

2024 Market Size 466.56 (USD Million)
2035 Market Size 1144.78 (USD Million)
CAGR (2025 - 2035) 8.5%
Largest Regional Market Share in 2024 North America

Major Players

Johnson & Johnson (US), Medtronic (US), Stryker Corporation (US), Zimmer Biomet (US), Abbott Laboratories (US), Baxter International (US), Smith & Nephew (GB), DePuy Synthes (US), Boston Scientific (US)

Market Trends

The Thumb Arthritis Market is currently experiencing notable transformations driven by various factors. Increasing awareness regarding the condition, coupled with advancements in treatment options, appears to be influencing patient choices significantly. The prevalence of thumb arthritis, particularly among older adults, seems to be rising, which may lead to a greater demand for effective management solutions. Furthermore, the integration of technology in treatment modalities, such as telemedicine and digital health applications, is likely to enhance patient engagement and adherence to prescribed therapies. This evolving landscape suggests a shift towards more personalized and accessible care for individuals suffering from this debilitating condition. In addition, the Thumb Arthritis Market is witnessing a growing emphasis on preventive measures and early intervention strategies. Healthcare providers are increasingly focusing on educating patients about lifestyle modifications and ergonomic practices that could mitigate the onset of symptoms. This proactive approach may not only improve patient outcomes but also reduce the overall burden on healthcare systems. As the market continues to evolve, stakeholders must remain vigilant to emerging trends and adapt their strategies accordingly to meet the changing needs of patients and healthcare providers alike.

Technological Integration in Treatment

The incorporation of technology into treatment protocols is becoming more prevalent in the Thumb Arthritis Market. Innovations such as telehealth services and mobile health applications are facilitating remote consultations and monitoring, which may enhance patient compliance and satisfaction.

Focus on Preventive Care

There is a noticeable shift towards preventive care within the Thumb Arthritis Market. Healthcare professionals are prioritizing education on lifestyle changes and ergonomic practices, which could potentially delay the progression of symptoms and improve quality of life for patients.

Personalized Treatment Approaches

The trend towards personalized medicine is gaining traction in the Thumb Arthritis Market. Tailoring treatment plans to individual patient needs and preferences may lead to better outcomes and increased patient engagement in their own care.

Thumb Arthritis Market Market Drivers

Market Growth Projections

The Global Thumb Arthritis Market Industry is projected to experience substantial growth over the next decade. With a market value of 0.47 USD Billion in 2024, it is anticipated to reach 1.15 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.48% from 2025 to 2035. This growth trajectory indicates a robust demand for treatment options and innovations in the field of thumb arthritis. Stakeholders in the industry must remain vigilant in adapting to changing market dynamics and consumer needs to capitalize on this promising growth opportunity.

Rising Geriatric Population

The aging population worldwide is a critical driver of the Global Thumb Arthritis Market Industry. As individuals age, the likelihood of developing osteoarthritis, including thumb arthritis, increases. This demographic shift is particularly pronounced in developed countries, where healthcare systems are increasingly focused on managing chronic conditions associated with aging. The growing geriatric population is expected to lead to a higher incidence of thumb arthritis, thereby driving demand for treatment options. With the market projected to reach 1.15 USD Billion by 2035, addressing the needs of this demographic will be essential for stakeholders in the industry.

Growing Awareness and Education

The Global Thumb Arthritis Market Industry benefits from increasing awareness and education regarding thumb arthritis. Public health campaigns and educational initiatives are helping to inform individuals about the symptoms, risk factors, and treatment options available. This heightened awareness encourages early diagnosis and intervention, which can significantly improve patient outcomes. As more people become informed about thumb arthritis, the demand for medical consultations and therapeutic interventions is likely to rise. Consequently, this trend may contribute to the market's growth, as healthcare systems adapt to meet the needs of a more informed patient population.

Advancements in Treatment Options

Innovations in the treatment landscape for thumb arthritis are significantly influencing the Global Thumb Arthritis Market Industry. The development of minimally invasive surgical techniques, biologics, and advanced pharmacological therapies is enhancing patient outcomes. These advancements not only improve the quality of life for patients but also expand the range of available treatment options. As healthcare providers adopt these new technologies, the market is likely to see increased investment and growth. The anticipated compound annual growth rate (CAGR) of 8.48% from 2025 to 2035 underscores the potential for continued expansion driven by these advancements.

Increasing Prevalence of Thumb Arthritis

The Global Thumb Arthritis Market Industry is experiencing growth due to the rising prevalence of thumb arthritis among various demographics. Factors such as aging populations and increased participation in activities that strain the thumb joint contribute to this trend. In 2024, the market is valued at approximately 0.47 USD Billion, reflecting the growing need for effective treatment options. As awareness of thumb arthritis increases, more individuals seek medical attention, thereby driving demand for innovative therapies and products. This trend is expected to continue, with projections indicating a market value of 1.15 USD Billion by 2035, suggesting a robust growth trajectory.

Increased Participation in Sports and Physical Activities

The Global Thumb Arthritis Market Industry is also influenced by the rising participation in sports and physical activities, which can lead to thumb injuries and subsequent arthritis. As more individuals engage in recreational and competitive sports, the incidence of thumb-related injuries may rise, contributing to the development of arthritis. This trend is particularly relevant among younger populations, who may experience long-term consequences from acute injuries. The market's growth is likely to be fueled by the need for preventive measures and treatments for thumb arthritis, as awareness of the connection between sports participation and joint health continues to grow.

Market Segment Insights

By Type of Arthritis: Osteoarthritis (Largest) vs. Rheumatoid Arthritis (Fastest-Growing)

The thumb arthritis market is significantly influenced by the prevalence of various types of arthritis, with osteoarthritis dominating the segment due to its high incidence among the aging population. This condition accounts for a substantial market share, as it commonly affects the cartilage in the thumb joint. <a href="https://www.marketresearchfuture.com/reports/rheumatoid-arthritis-market-1658" target="_blank" title="rheumatoid arthritis">Rheumatoid arthritis</a>, although less common than osteoarthritis, is witnessing a surge in cases, driving a notable growth in awareness and treatment options among patients. Recent trends indicate that the rheumatoid arthritis segment is the fastest-growing category within the thumb arthritis market. This growth is fueled by increased diagnosis rates, advancements in therapy options, and a rising number of anti-rheumatic drugs entering the market. Additionally, emphasis on early intervention and the benefits of personalized treatment plans contribute to the growth in this segment, positioning it as a key area of focus for medical providers and policymakers alike.

Osteoarthritis (Dominant) vs. Gout (Emerging)

Osteoarthritis remains the dominant segment within the thumb arthritis market, as it primarily affects older individuals who experience wear and tear of the joints over time. The characteristics of osteoarthritis include joint pain, stiffness, and limited mobility, all of which markedly affect the quality of life. In contrast, gout is emerging as a significant segment due to the increasing awareness of metabolic disorders and lifestyle diseases that contribute to its prevalence. Gout is characterized by sudden and severe attacks of pain, redness, and swelling, often linked to high levels of uric acid in the bloodstream. As public awareness grows and new diagnostic methods advance, gout is quickly becoming a focal point in arthritis discussions, prompting further research and treatment innovations.

By Treatment Type: Medication (Largest) vs. Physical Therapy (Fastest-Growing)

<p>In the Thumb Arthritis Market, the treatment type segmentation reveals a diverse distribution among four main categories: Medication, Physical Therapy, Surgical Intervention, and Assistive Devices. Medication holds the largest portion of the market share, attributed to its widespread acceptance and usage in managing pain and inflammation associated with thumb arthritis. Following this, Assistive Devices play a significant role in aiding patients in daily tasks, while Surgical Intervention remains a critical option for severe cases, albeit with a smaller market presence. Physical Therapy is emerging as a popular choice due to its holistic approach to treatment, gaining increasing traction among patients seeking non-invasive options.</p>

<p>Medication (Dominant) vs. Physical Therapy (Emerging)</p>

<p>Medication is currently the dominant treatment option in the Thumb Arthritis Market, primarily due to its effectiveness in alleviating pain and improving function. It encompasses a range of formulations from over-the-counter NSAIDs to <a href="https://www.marketresearchfuture.com/reports/prescription-drugs-market-43718" target="_blank" title="prescription drugs">prescription drugs</a> specifically targeting inflammation. On the other hand, Physical Therapy is an emerging segment, rapidly gaining recognition for its role in rehabilitating patients and improving mobility without invasive procedures. Tailored therapy sessions help patients strengthen thumb muscles and improve flexibility, presenting a patient-centric alternative. As healthcare trends shift towards conservative management of thumb arthritis, the demand for physical therapy is projected to rise, emphasizing preventive care and maintaining functional independence.</p>

By Age Group: Adults (Largest) vs. Elderly (Fastest-Growing)

The Thumb Arthritis Market exhibits a distinct distribution of cases across various age groups, with adults representing the largest segment. This demographic accounts for a significant proportion of thumb arthritis cases due to lifestyle factors, work-related stressors, and general wear and tear that accompany midlife. In contrast, the elderly segment, while smaller, is experiencing a surge in cases as the population ages and people live longer, increasing exposure to joint-related issues as well as the natural degeneration of joint health during the aging process.

Adults (Dominant) vs. Elderly (Emerging)

In the Thumb Arthritis Market, the adult segment stands out as the dominant force, primarily due to their active lifestyles which can lead to higher susceptibility to thumb joint issues. Adults often engage in repetitive tasks that strain the thumb, resulting in an increased incidence of arthritis. Meanwhile, the elderly demographic is emerging as a crucial segment, driven by an aging population that is living longer and staying more active. This shift emphasizes the need for targeted treatment options and preventative measures for aging individuals, who face a unique set of challenges related to thumb arthritis.

By Severity Level: Moderate (Largest) vs. Severe (Fastest-Growing)

The Thumb Arthritis Market shows a diverse distribution across the severity levels of mild, moderate, and severe arthritis. The moderate severity level dominates the market, holding the largest share as it reflects the most common diagnosis among patients. Mild cases tend to be overlooked in clinical settings, while severe cases, although less frequent, generate substantial demand for advanced treatment options. This distribution indicates a nuanced understanding of patient needs, with moderate severity cases being crucial for therapeutic interventions.

Moderate (Dominant) vs. Severe (Emerging)

In the Thumb Arthritis Market, the moderate severity level is characterized by patients who experience noticeable functional limitations and discomfort but have not reached the extremes of severity. This segment benefits from a range of treatment options including conservative therapies and lifestyle modifications. Conversely, the severe severity level encompasses more challenging conditions, frequently involving chronic pain and significant disability. As awareness grows and targeted therapies emerge, this segment shows a rapidly accelerating demand, driven by advancements in treatment modalities and an aging population. The diverse needs of these two segments highlight the importance of tailored therapeutic approaches in improving patient outcomes.

By Gender: Female (Largest) vs. Male (Fastest-Growing)

In the Thumb Arthritis Market, the distribution of market share among gender segments reveals that females represent the largest proportion, largely due to higher prevalence rates linked to anatomical and hormonal factors. Males, while forming a smaller share of the market, are experiencing faster growth as awareness and diagnosis of thumb arthritis increase among this demographic, aided by changes in lifestyle and occupational hazards that lead to rising incidence rates. The growth trends for the gender segment indicate an evolving awareness of thumb arthritis and its treatments. Increased education about the condition is leading to more men seeking therapy, thus propelling the male segment's expansion. Additionally, the female segment remains robust as ongoing research continues to uncover more about the gender-specific conditions related to arthritis, fueling demand for targeted therapies and support systems.

Gender: Female (Dominant) vs. Male (Emerging)

The female segment of the Thumb Arthritis Market is dominant, primarily due to the higher prevalence of arthritis conditions in women as they age, driven by factors such as hormonal changes and anatomical differences. The market for femal-specific treatments is well-established, with numerous options available for management and pain relief. They often benefit from targeted therapies that address their unique needs, contributing to their market leadership. Meanwhile, the male segment is emerging as an important focus area, characterized by increasing awareness and diagnosis of thumb arthritis among men. This growing recognition is attributed to lifestyle changes and increasing engagement in preventative healthcare measures. As more targeted solutions are developed, the male segment is set to experience significant growth, making it a key area for future market development.

Get more detailed insights about Thumb Arthritis Market Research Report - Global Forecast till 2035

Regional Insights

North America : Market Leader in Innovation

North America is poised to maintain its leadership in the Thumb Arthritis market, holding a significant market share of $233.28M in 2024. The region's growth is driven by an aging population, increasing prevalence of arthritis, and advancements in medical technology. Regulatory support for innovative treatments and devices further fuels demand, ensuring a robust market environment. The competitive landscape is characterized by major players such as Johnson & Johnson, Medtronic, and Stryker Corporation, which are at the forefront of developing cutting-edge solutions. The U.S. remains the largest market, supported by strong healthcare infrastructure and high healthcare expenditure. This dynamic environment fosters continuous innovation and enhances patient access to effective treatments.

Europe : Emerging Market with Growth Potential

Europe's Thumb Arthritis market is valued at $130.0M, reflecting a growing demand for effective treatment options. Key growth drivers include an increasing elderly population and rising awareness of arthritis management. Regulatory frameworks in the EU are evolving to support innovative therapies, which is expected to enhance market growth. Leading countries such as Germany, France, and the UK are pivotal in this market, with a strong presence of key players like Smith & Nephew and Zimmer Biomet. The competitive landscape is marked by collaborations and partnerships aimed at enhancing product offerings. As the market matures, the focus on patient-centric solutions is likely to drive further growth.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific Thumb Arthritis market, valued at $80.0M, is experiencing rapid growth due to increasing healthcare access and rising awareness of arthritis treatments. The region's expanding middle class and aging population are significant demand drivers. Regulatory bodies are also becoming more supportive of new medical technologies, which is expected to enhance market dynamics. Countries like Japan, China, and Australia are leading the market, with a growing number of local and international players entering the space. Companies such as Abbott Laboratories and Boston Scientific are focusing on innovative solutions tailored to regional needs. The competitive landscape is evolving, with an emphasis on affordability and accessibility of treatments.

Middle East and Africa : Emerging Market with Challenges

The Middle East & Africa Thumb Arthritis market, valued at $23.28M, is still in its nascent stages but shows potential for growth. Key drivers include increasing healthcare investments and a rising prevalence of arthritis. However, challenges such as limited access to advanced medical technologies and varying regulatory environments can hinder market expansion. Countries like South Africa and the UAE are leading the market, with a growing interest from international players. The competitive landscape is characterized by a mix of local and global companies, focusing on affordable treatment options. As healthcare infrastructure improves, the market is expected to evolve, providing better access to innovative therapies.

Key Players and Competitive Insights

The Thumb Arthritis Market is currently characterized by a competitive landscape that is both dynamic and multifaceted. Key growth drivers include an aging population, increasing prevalence of arthritis, and advancements in treatment technologies. Major players such as Johnson & Johnson (US), Medtronic (US), and Stryker Corporation (US) are strategically positioned to leverage these trends. Johnson & Johnson (US) focuses on innovation through its extensive research and development initiatives, while Medtronic (US) emphasizes digital transformation and the integration of AI in its product offerings. Stryker Corporation (US) is actively pursuing mergers and acquisitions to enhance its portfolio, thereby shaping a competitive environment that is increasingly reliant on technological advancements and strategic partnerships.In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains, which is particularly crucial in a moderately fragmented market. The collective influence of these key players is significant, as they not only drive innovation but also set industry standards that smaller competitors must follow. This competitive structure allows for a diverse range of products and services, catering to various consumer needs while fostering a culture of continuous improvement.

In November Johnson & Johnson (US) announced a strategic partnership with a leading tech firm to develop a new AI-driven platform aimed at enhancing patient outcomes in thumb arthritis treatment. This collaboration is expected to streamline patient monitoring and improve treatment efficacy, reflecting the company's commitment to integrating cutting-edge technology into its offerings. Such initiatives are likely to position Johnson & Johnson (US) as a leader in the market, emphasizing the importance of innovation in maintaining competitive advantage.

In October Medtronic (US) launched a new line of minimally invasive surgical tools specifically designed for thumb arthritis procedures. This product line not only addresses the growing demand for less invasive treatment options but also aligns with the company's strategy to enhance patient recovery times and reduce healthcare costs. The introduction of these tools signifies Medtronic's proactive approach to meeting market needs and underscores the potential for growth in this segment.

In September Stryker Corporation (US) completed the acquisition of a smaller competitor specializing in orthopedic devices, which is anticipated to expand its market share in the thumb arthritis sector. This acquisition is strategically important as it allows Stryker to diversify its product offerings and enhance its technological capabilities, thereby reinforcing its competitive position. The move illustrates a broader trend of consolidation within the market, as companies seek to bolster their portfolios through strategic acquisitions.

As of December current competitive trends are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and innovative treatment solutions. This shift suggests that companies that prioritize R&D and strategic partnerships will be better positioned to thrive in the evolving landscape of the Thumb Arthritis Market.

Key Companies in the Thumb Arthritis Market include

Industry Developments

February 2023 In an announcement, Roche stated that it had intensified its partnership with Janssen Biotech Inc. (Janssen) to develop companion diagnostics for targeted treatments.

July 2018 A single injectable viscosupplement called MONOVISC is offered by Anika Therapeutics Inc. It contains cross-linked sodium hyaluronate in phosphate-buffered saline solution. This is employed in the treatment of osteoarthritis-related joint pain.

June 2020 One of the top businesses, Horizon Therapeutics Plc (UK), increased its market share in the US.

February 2020 Voltaren was introduced in the US by Glaxosmithkline Plc, the most well-known business.

Future Outlook

Thumb Arthritis Market Future Outlook

The Thumb Arthritis Market is projected to grow at an 8.5% CAGR from 2025 to 2035, driven by increasing prevalence, technological advancements, and rising awareness.

New opportunities lie in:

  • Development of telehealth platforms for remote consultations and follow-ups.
  • Investment in innovative biomaterials for <a href="https://www.marketresearchfuture.com/reports/joint-replacement-market-43209" target="_blank" title="joint replacement">joint replacement</a> devices.
  • Expansion of targeted marketing strategies for aging populations in emerging markets.

By 2035, the Thumb Arthritis Market is expected to achieve substantial growth, reflecting evolving consumer needs and technological advancements.

Market Segmentation

Thumb Arthritis Market Gender Outlook

  • Male
  • Female
  • Non-Binary

Thumb Arthritis Market Age Group Outlook

  • Children
  • Adults
  • Elderly

Thumb Arthritis Market Severity Level Outlook

  • Mild
  • Moderate
  • Severe

Thumb Arthritis Market Treatment Type Outlook

  • Medication
  • Physical Therapy
  • Surgical Intervention
  • Assistive Devices

Thumb Arthritis Market Type of Arthritis Outlook

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Post-Traumatic Arthritis
  • Gout

Report Scope

MARKET SIZE 2024 466.56(USD Million)
MARKET SIZE 2025 506.23(USD Million)
MARKET SIZE 2035 1144.78(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 8.5% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Johnson & Johnson (US), Medtronic (US), Stryker Corporation (US), Zimmer Biomet (US), Abbott Laboratories (US), Baxter International (US), Smith & Nephew (GB), DePuy Synthes (US), Boston Scientific (US)
Segments Covered Type of Arthritis, Treatment Type, Age Group, Severity Level, Gender
Key Market Opportunities Advancements in minimally invasive treatments enhance patient outcomes in the Thumb Arthritis Market.
Key Market Dynamics Rising demand for innovative treatment options drives competition and technological advancements in the Thumb Arthritis Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Thumb Arthritis Market?

<p>The Thumb Arthritis Market was valued at 466.56 USD Million in 2024.</p>

What is the projected market size for the Thumb Arthritis Market by 2035?

<p>The market is expected to reach 1144.78 USD Million by 2035.</p>

What is the expected CAGR for the Thumb Arthritis Market during the forecast period?

<p>The expected CAGR for the Thumb Arthritis Market from 2025 to 2035 is 8.5%.</p>

Which types of arthritis are included in the Thumb Arthritis Market segmentation?

<p>The market segments include Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, and Gout.</p>

What were the market values for Osteoarthritis and Rheumatoid Arthritis in 2024?

<p>In 2024, Osteoarthritis was valued at 186.56 USD Million, while Rheumatoid Arthritis was valued at 120.0 USD Million.</p>

How does the market for assistive devices compare to other treatment types?

<p>Assistive Devices were valued at 93.31 USD Million in 2024, similar to Physical Therapy and Surgical Intervention.</p>

What age groups are represented in the Thumb Arthritis Market?

The market segments by age group include Children, Adults, and the Elderly.

What were the market values for the elderly and adults in 2024?

In 2024, the market value for the Elderly was 166.56 USD Million, while Adults accounted for 250.0 USD Million.

Which companies are considered key players in the Thumb Arthritis Market?

Key players include Johnson &amp; Johnson, Medtronic, Stryker Corporation, and Zimmer Biomet.

What severity levels are recognized in the Thumb Arthritis Market?

The market recognizes Mild, Moderate, and Severe severity levels, with Moderate valued at 186.88 USD Million in 2024.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Type of Arthritis (USD Million)
    2. | | 4.1.1 Osteoarthritis
    3. | | 4.1.2 Rheumatoid Arthritis
    4. | | 4.1.3 Post-Traumatic Arthritis
    5. | | 4.1.4 Gout
    6. | 4.2 Healthcare, BY Treatment Type (USD Million)
    7. | | 4.2.1 Medication
    8. | | 4.2.2 Physical Therapy
    9. | | 4.2.3 Surgical Intervention
    10. | | 4.2.4 Assistive Devices
    11. | 4.3 Healthcare, BY Age Group (USD Million)
    12. | | 4.3.1 Children
    13. | | 4.3.2 Adults
    14. | | 4.3.3 Elderly
    15. | 4.4 Healthcare, BY Severity Level (USD Million)
    16. | | 4.4.1 Mild
    17. | | 4.4.2 Moderate
    18. | | 4.4.3 Severe
    19. | 4.5 Healthcare, BY Region (USD Million)
    20. | | 4.5.1 North America
    21. | | | 4.5.1.1 US
    22. | | | 4.5.1.2 Canada
    23. | | 4.5.2 Europe
    24. | | | 4.5.2.1 Germany
    25. | | | 4.5.2.2 UK
    26. | | | 4.5.2.3 France
    27. | | | 4.5.2.4 Russia
    28. | | | 4.5.2.5 Italy
    29. | | | 4.5.2.6 Spain
    30. | | | 4.5.2.7 Rest of Europe
    31. | | 4.5.3 APAC
    32. | | | 4.5.3.1 China
    33. | | | 4.5.3.2 India
    34. | | | 4.5.3.3 Japan
    35. | | | 4.5.3.4 South Korea
    36. | | | 4.5.3.5 Malaysia
    37. | | | 4.5.3.6 Thailand
    38. | | | 4.5.3.7 Indonesia
    39. | | | 4.5.3.8 Rest of APAC
    40. | | 4.5.4 South America
    41. | | | 4.5.4.1 Brazil
    42. | | | 4.5.4.2 Mexico
    43. | | | 4.5.4.3 Argentina
    44. | | | 4.5.4.4 Rest of South America
    45. | | 4.5.5 MEA
    46. | | | 4.5.5.1 GCC Countries
    47. | | | 4.5.5.2 South Africa
    48. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Johnson & Johnson (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Medtronic (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Stryker Corporation (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Zimmer Biomet (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Abbott Laboratories (US)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Baxter International (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Smith & Nephew (GB)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Boston Scientific (US)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 DePuy Synthes (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TYPE OF ARTHRITIS
    4. | 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
    5. | 6.5 US MARKET ANALYSIS BY AGE GROUP
    6. | 6.6 US MARKET ANALYSIS BY SEVERITY LEVEL
    7. | 6.7 CANADA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    8. | 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
    9. | 6.9 CANADA MARKET ANALYSIS BY AGE GROUP
    10. | 6.10 CANADA MARKET ANALYSIS BY SEVERITY LEVEL
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY TYPE OF ARTHRITIS
    13. | 6.13 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
    14. | 6.14 GERMANY MARKET ANALYSIS BY AGE GROUP
    15. | 6.15 GERMANY MARKET ANALYSIS BY SEVERITY LEVEL
    16. | 6.16 UK MARKET ANALYSIS BY TYPE OF ARTHRITIS
    17. | 6.17 UK MARKET ANALYSIS BY TREATMENT TYPE
    18. | 6.18 UK MARKET ANALYSIS BY AGE GROUP
    19. | 6.19 UK MARKET ANALYSIS BY SEVERITY LEVEL
    20. | 6.20 FRANCE MARKET ANALYSIS BY TYPE OF ARTHRITIS
    21. | 6.21 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
    22. | 6.22 FRANCE MARKET ANALYSIS BY AGE GROUP
    23. | 6.23 FRANCE MARKET ANALYSIS BY SEVERITY LEVEL
    24. | 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    25. | 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
    26. | 6.26 RUSSIA MARKET ANALYSIS BY AGE GROUP
    27. | 6.27 RUSSIA MARKET ANALYSIS BY SEVERITY LEVEL
    28. | 6.28 ITALY MARKET ANALYSIS BY TYPE OF ARTHRITIS
    29. | 6.29 ITALY MARKET ANALYSIS BY TREATMENT TYPE
    30. | 6.30 ITALY MARKET ANALYSIS BY AGE GROUP
    31. | 6.31 ITALY MARKET ANALYSIS BY SEVERITY LEVEL
    32. | 6.32 SPAIN MARKET ANALYSIS BY TYPE OF ARTHRITIS
    33. | 6.33 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
    34. | 6.34 SPAIN MARKET ANALYSIS BY AGE GROUP
    35. | 6.35 SPAIN MARKET ANALYSIS BY SEVERITY LEVEL
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF ARTHRITIS
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY SEVERITY LEVEL
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    42. | 6.42 CHINA MARKET ANALYSIS BY TREATMENT TYPE
    43. | 6.43 CHINA MARKET ANALYSIS BY AGE GROUP
    44. | 6.44 CHINA MARKET ANALYSIS BY SEVERITY LEVEL
    45. | 6.45 INDIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    46. | 6.46 INDIA MARKET ANALYSIS BY TREATMENT TYPE
    47. | 6.47 INDIA MARKET ANALYSIS BY AGE GROUP
    48. | 6.48 INDIA MARKET ANALYSIS BY SEVERITY LEVEL
    49. | 6.49 JAPAN MARKET ANALYSIS BY TYPE OF ARTHRITIS
    50. | 6.50 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
    51. | 6.51 JAPAN MARKET ANALYSIS BY AGE GROUP
    52. | 6.52 JAPAN MARKET ANALYSIS BY SEVERITY LEVEL
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY SEVERITY LEVEL
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY AGE GROUP
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY SEVERITY LEVEL
    61. | 6.61 THAILAND MARKET ANALYSIS BY TYPE OF ARTHRITIS
    62. | 6.62 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
    63. | 6.63 THAILAND MARKET ANALYSIS BY AGE GROUP
    64. | 6.64 THAILAND MARKET ANALYSIS BY SEVERITY LEVEL
    65. | 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    66. | 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
    67. | 6.67 INDONESIA MARKET ANALYSIS BY AGE GROUP
    68. | 6.68 INDONESIA MARKET ANALYSIS BY SEVERITY LEVEL
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF ARTHRITIS
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY AGE GROUP
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY SEVERITY LEVEL
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF ARTHRITIS
    75. | 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
    76. | 6.76 BRAZIL MARKET ANALYSIS BY AGE GROUP
    77. | 6.77 BRAZIL MARKET ANALYSIS BY SEVERITY LEVEL
    78. | 6.78 MEXICO MARKET ANALYSIS BY TYPE OF ARTHRITIS
    79. | 6.79 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
    80. | 6.80 MEXICO MARKET ANALYSIS BY AGE GROUP
    81. | 6.81 MEXICO MARKET ANALYSIS BY SEVERITY LEVEL
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY AGE GROUP
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY SEVERITY LEVEL
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SEVERITY LEVEL
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF ARTHRITIS
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY SEVERITY LEVEL
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY SEVERITY LEVEL
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF ARTHRITIS
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY AGE GROUP
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY SEVERITY LEVEL
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY TYPE OF ARTHRITIS, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY TYPE OF ARTHRITIS, 2024 TO 2035 (USD Million)
    111. | 6.111 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    113. | 6.113 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
    115. | 6.115 HEALTHCARE, BY SEVERITY LEVEL, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY SEVERITY LEVEL, 2024 TO 2035 (USD Million)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    5. | | 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    6. | | 7.2.3 BY AGE GROUP, 2025-2035 (USD Million)
    7. | | 7.2.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    10. | | 7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    11. | | 7.3.3 BY AGE GROUP, 2025-2035 (USD Million)
    12. | | 7.3.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    15. | | 7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    16. | | 7.4.3 BY AGE GROUP, 2025-2035 (USD Million)
    17. | | 7.4.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    20. | | 7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    21. | | 7.5.3 BY AGE GROUP, 2025-2035 (USD Million)
    22. | | 7.5.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    25. | | 7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    26. | | 7.6.3 BY AGE GROUP, 2025-2035 (USD Million)
    27. | | 7.6.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    30. | | 7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    31. | | 7.7.3 BY AGE GROUP, 2025-2035 (USD Million)
    32. | | 7.7.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    35. | | 7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    36. | | 7.8.3 BY AGE GROUP, 2025-2035 (USD Million)
    37. | | 7.8.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    40. | | 7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    41. | | 7.9.3 BY AGE GROUP, 2025-2035 (USD Million)
    42. | | 7.9.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    45. | | 7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    46. | | 7.10.3 BY AGE GROUP, 2025-2035 (USD Million)
    47. | | 7.10.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    50. | | 7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    51. | | 7.11.3 BY AGE GROUP, 2025-2035 (USD Million)
    52. | | 7.11.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    55. | | 7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    56. | | 7.12.3 BY AGE GROUP, 2025-2035 (USD Million)
    57. | | 7.12.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    60. | | 7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    61. | | 7.13.3 BY AGE GROUP, 2025-2035 (USD Million)
    62. | | 7.13.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    65. | | 7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    66. | | 7.14.3 BY AGE GROUP, 2025-2035 (USD Million)
    67. | | 7.14.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    70. | | 7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    71. | | 7.15.3 BY AGE GROUP, 2025-2035 (USD Million)
    72. | | 7.15.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    75. | | 7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    76. | | 7.16.3 BY AGE GROUP, 2025-2035 (USD Million)
    77. | | 7.16.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    80. | | 7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    81. | | 7.17.3 BY AGE GROUP, 2025-2035 (USD Million)
    82. | | 7.17.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    85. | | 7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    86. | | 7.18.3 BY AGE GROUP, 2025-2035 (USD Million)
    87. | | 7.18.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    90. | | 7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    91. | | 7.19.3 BY AGE GROUP, 2025-2035 (USD Million)
    92. | | 7.19.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    95. | | 7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    96. | | 7.20.3 BY AGE GROUP, 2025-2035 (USD Million)
    97. | | 7.20.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    100. | | 7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    101. | | 7.21.3 BY AGE GROUP, 2025-2035 (USD Million)
    102. | | 7.21.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    105. | | 7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    106. | | 7.22.3 BY AGE GROUP, 2025-2035 (USD Million)
    107. | | 7.22.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    110. | | 7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    111. | | 7.23.3 BY AGE GROUP, 2025-2035 (USD Million)
    112. | | 7.23.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    115. | | 7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    116. | | 7.24.3 BY AGE GROUP, 2025-2035 (USD Million)
    117. | | 7.24.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    120. | | 7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    121. | | 7.25.3 BY AGE GROUP, 2025-2035 (USD Million)
    122. | | 7.25.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    125. | | 7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    126. | | 7.26.3 BY AGE GROUP, 2025-2035 (USD Million)
    127. | | 7.26.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    130. | | 7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    131. | | 7.27.3 BY AGE GROUP, 2025-2035 (USD Million)
    132. | | 7.27.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    135. | | 7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    136. | | 7.28.3 BY AGE GROUP, 2025-2035 (USD Million)
    137. | | 7.28.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    140. | | 7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    141. | | 7.29.3 BY AGE GROUP, 2025-2035 (USD Million)
    142. | | 7.29.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
    145. | | 7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
    146. | | 7.30.3 BY AGE GROUP, 2025-2035 (USD Million)
    147. | | 7.30.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Type of Arthritis (USD Million, 2025-2035)

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Post-Traumatic Arthritis
  • Gout

Healthcare By Treatment Type (USD Million, 2025-2035)

  • Medication
  • Physical Therapy
  • Surgical Intervention
  • Assistive Devices

Healthcare By Age Group (USD Million, 2025-2035)

  • Children
  • Adults
  • Elderly

Healthcare By Severity Level (USD Million, 2025-2035)

  • Mild
  • Moderate
  • Severe
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓